MA30965B1 - Molecules de liaison a lingo et utilisation pharmaceutique de celles-ci - Google Patents

Molecules de liaison a lingo et utilisation pharmaceutique de celles-ci

Info

Publication number
MA30965B1
MA30965B1 MA31944A MA31944A MA30965B1 MA 30965 B1 MA30965 B1 MA 30965B1 MA 31944 A MA31944 A MA 31944A MA 31944 A MA31944 A MA 31944A MA 30965 B1 MA30965 B1 MA 30965B1
Authority
MA
Morocco
Prior art keywords
binding molecule
binding molecules
polynucleotide
pharmaceutical use
lingo
Prior art date
Application number
MA31944A
Other languages
English (en)
Inventor
Adrien Walmsley
William Leonard Wishart
Marta Cortes-Cros
Josef Prassler
Ingo Klagge
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38325542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30965(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30965B1 publication Critical patent/MA30965B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE MOLÉCULE DE LIAISON QUI EST CAPABLE DE SE LIER AU POLYPEPTIDE LINGO HUMAIN, DE SINGE CYNOMOLGUS ET DE RAT, UN POLYNUCLÉOTIDE CODANT POUR UNE TELLE MOLÉCULE DE LIAISON ; UN VECTEUR D'EXPRESSION COMPRENANT LEDIT POLYNUCLÉOTIDE ; UN SYSTÈME D'EXPRESSION COMPRENANT UN POLYNUCLÉOTIDE CAPABLE DE PRODUIRE UNE MOLÉCULE DE LIAISON ; UNE CELLULE HÔTE ISOLÉE QUI COMPREND UN SYSTÈME D'EXPRESSION TEL QUE DÉFINI CI-DESSUS ; L'UTILISATION D'UNE TELLE MOLÉCULE DE LIAISON EN TANT QU'UN PRODUIT PHARMACEUTIQUE, NOTAMMENT DANS LE TRAITEMENT DESTINÉ À PROMOUVOIR LA RÉGÉNÉRATION/PLASTICITÉ AXONALE ; UNE COMPOSITION PHARMACEUTIQUE COMPRENANT LADITE MOLÉCULE DE LIAISON ; ET UN PROCÉDÉ DE TRAITEMENT DE MALADIES ASSOCIÉES À LA DÉGÉNÉRESCENCE AXONALE ET À LA DÉMYÉLINISATION.
MA31944A 2006-11-17 2009-06-03 Molecules de liaison a lingo et utilisation pharmaceutique de celles-ci MA30965B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06124350 2006-11-17

Publications (1)

Publication Number Publication Date
MA30965B1 true MA30965B1 (fr) 2009-12-01

Family

ID=38325542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31944A MA30965B1 (fr) 2006-11-17 2009-06-03 Molecules de liaison a lingo et utilisation pharmaceutique de celles-ci

Country Status (27)

Country Link
US (4) US8299221B2 (fr)
EP (2) EP2084190B1 (fr)
JP (2) JP5647414B2 (fr)
KR (1) KR20090078353A (fr)
CN (2) CN101553506B (fr)
AR (1) AR063829A1 (fr)
AT (1) ATE502960T1 (fr)
AU (1) AU2007321817A1 (fr)
BR (1) BRPI0718406A2 (fr)
CA (1) CA2669181A1 (fr)
CL (1) CL2007003303A1 (fr)
CO (1) CO6180433A2 (fr)
CR (1) CR10756A (fr)
DE (1) DE602007013445D1 (fr)
EC (1) ECSP099332A (fr)
ES (1) ES2363622T3 (fr)
GT (1) GT200900121A (fr)
IL (1) IL198313A0 (fr)
MA (1) MA30965B1 (fr)
MX (1) MX2009005175A (fr)
NO (1) NO20092331L (fr)
PE (1) PE20081392A1 (fr)
RU (1) RU2009122514A (fr)
TN (1) TN2009000190A1 (fr)
TW (1) TW200831534A (fr)
WO (1) WO2008058736A1 (fr)
ZA (1) ZA200902409B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2902491A1 (fr) 2003-03-19 2015-08-05 Biogen MA Inc. Protéine de liaison du récepteur NOGO
EP1776136B1 (fr) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Traitement d'etats pathologiques impliquant la demyelinisation
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
NZ569428A (en) * 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
EP2068866A4 (fr) 2006-07-24 2010-04-07 Biogen Idec Inc Procedes pour favoriser la myelinisation, la survie neuronale et la differenciation des oligodendrocytes par administration d'antagonistes de sp35 ou trka
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CA2701189C (fr) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methodes permettant de traiter la neuropathie optique induite par la pression, de prevenir la degenerescence des neurones et de favoriser la survie des neurones par l'administration d'antagonistes de lingo-1 et d'agonistes de trkb
JP5754046B2 (ja) * 2007-11-08 2015-07-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄を伴う状態の治療におけるｌｉｎｇｏ−４アンタゴニストの使用
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
CN103118692A (zh) 2010-04-26 2013-05-22 Atyr医药公司 与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6240500B2 (ja) 2010-04-27 2017-11-29 エータイアー ファーマ， インコーポレイテッド スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2797362C (fr) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps se rapportant a des fragments proteiques d'isoleucyl arnt synthetases
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
ES2623805T3 (es) 2010-05-03 2017-07-12 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
EP2566496B1 (fr) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées des fragments protéiques de méthionyl-arnt-synthétases
WO2011139988A2 (fr) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à des fragments protéiques de séryle-arnt synthétases
CN102985103A (zh) 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
EP2566492B1 (fr) 2010-05-04 2016-10-26 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques liées à des fragments protéiques de glutamyl-prolyl-arnt-synthétases
CA2799197C (fr) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Decouverte de compositions inedites de nature therapeutique, diagnostique et a base d'anticorps contenant des fragments proteiques de phenylalanyl-beta-arnt synthetases
CA2799480C (fr) 2010-05-17 2020-12-15 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic, et d'anticorps associees a des fragments proteiques de leucyl-arnt synthetases
CA2800375C (fr) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps liees a fragments proteiques de glutaminyl-arnt synthetases
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
WO2012021249A2 (fr) 2010-07-12 2012-02-16 Atyr Pharma, Inc. DÉCOUVERTE INNOVANTE DE COMPOSITIONS THÉRAPEUTIQUES, DIAGNOSTIQUES ET D'ANTICORPS SE RAPPORTANT À DES FRAGMENTS PROTÉIQUES D' HISTIDYLE-ARNt SYNTHÉTASES
KR102099730B1 (ko) 2010-07-12 2020-04-16 에이티와이알 파마, 인코포레이티드 아스파르틸­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
CA2812795C (fr) 2010-10-06 2021-08-31 Atyr Pharma, Inc. Decouverte innovante de fragments de proteine de tryptophanyle arnt synthetases associes a des compositions therapeutiques, diagnostiques et d'anticorps
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
WO2013086216A1 (fr) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Aspartyl-arnt synthétases améliorées
WO2013086228A1 (fr) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Polypeptides aspartyl-arnt synthétase pégylés
EP2797959A4 (fr) 2011-12-29 2015-08-26 Atyr Pharma Inc Conjugués aspartyl-arnt synthétase-fc
US9248128B2 (en) 2012-01-27 2016-02-02 New York University Method for enhancing remyelination using GLI1 inhibitors
NZ702178A (en) * 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
ES2847383T3 (es) 2013-03-15 2021-08-03 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
WO2016112270A1 (fr) 2015-01-08 2016-07-14 Biogen Ma Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
US10383080B2 (en) * 2015-01-26 2019-08-13 Intel IP Corporation Device and method to improve horizontal and vertical positioning accuracy
BR112019000630A2 (pt) * 2016-07-13 2019-07-09 Biogen Ma Inc regimes de dosagem dos antagonistas de lingo-1 e usos para tratamento de distúrbios desmielinizante
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
KR102414826B1 (ko) 2020-06-18 2022-06-30 삼성전기주식회사 코일 부품

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
BR9007115A (pt) 1989-02-13 1991-11-26 Schering Ag Novo trombolitico
ES2352551T3 (es) * 2003-03-19 2011-02-21 Biogen Idec Ma Inc. Proteína de unión a receptor nogo.
EP2902491A1 (fr) * 2003-03-19 2015-08-05 Biogen MA Inc. Protéine de liaison du récepteur NOGO
US20050214288A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor
EP1776136B1 (fr) * 2004-06-24 2012-10-03 Biogen Idec MA Inc. Traitement d'etats pathologiques impliquant la demyelinisation
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof

Also Published As

Publication number Publication date
EP2395022A9 (fr) 2013-04-24
JP5647414B2 (ja) 2014-12-24
GT200900121A (es) 2011-11-11
MX2009005175A (es) 2009-08-07
EP2084190A1 (fr) 2009-08-05
US20130071400A1 (en) 2013-03-21
JP2013056888A (ja) 2013-03-28
TW200831534A (en) 2008-08-01
CA2669181A1 (fr) 2008-05-22
CL2007003303A1 (es) 2008-06-27
ZA200902409B (en) 2010-04-28
CN101553506B (zh) 2013-08-07
ES2363622T3 (es) 2011-08-10
US20140255415A1 (en) 2014-09-11
IL198313A0 (en) 2011-08-01
CN103351437A (zh) 2013-10-16
EP2084190B1 (fr) 2011-03-23
BRPI0718406A2 (pt) 2013-12-17
US20100143362A1 (en) 2010-06-10
CN101553506A (zh) 2009-10-07
AU2007321817A1 (en) 2008-05-22
CO6180433A2 (es) 2010-07-19
US20140037639A1 (en) 2014-02-06
JP2010509906A (ja) 2010-04-02
RU2009122514A (ru) 2010-12-27
DE602007013445D1 (de) 2011-05-05
TN2009000190A1 (en) 2010-10-18
NO20092331L (no) 2009-06-17
KR20090078353A (ko) 2009-07-17
EP2395022A1 (fr) 2011-12-14
ECSP099332A (es) 2009-06-30
PE20081392A1 (es) 2008-11-12
WO2008058736A1 (fr) 2008-05-22
CR10756A (es) 2009-06-04
ATE502960T1 (de) 2011-04-15
AR063829A1 (es) 2009-02-18
US8299221B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
MA30965B1 (fr) Molecules de liaison a lingo et utilisation pharmaceutique de celles-ci
Kumagai et al. ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation in cultured Swiss 3T3 cells.
Cai et al. Biodegradation of composite resin with ester linkages: Identifying human salivary enzyme activity with a potential role in the esterolytic process
Heuer et al. Mapping Features of HIV-1 Integrase Near Selected Sites on Viral and Target DNA Molecules in an Active Enzyme− DNA Complex by Photo-Cross-Linking
Philp et al. Thymosin β4 and a synthetic peptide containing its actin‐binding domain promote dermal wound repair in db/db diabetic mice and in aged mice
Longley et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product
Tarsio et al. Decreased interaction of fibronectin, type iv collagen, and heparin due to nonenzymic glycation. Implications for diabetes mellitus
Williams et al. Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide
RU2009135802A (ru) Способ активации хелперных т-клеток и композиция для применения в данном способе
ATE527279T1 (de) Zusammensetzungen und verfahren zur modulation des immunsystems
HUP0202532A2 (hu) Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása
MA31805B1 (fr) Molécules améliorées de liaison à nogo-a et utilisation pharmaceutique de celles-ci
Gesteira et al. Lumican peptides: rational design targeting ALK5/TGFBRI
Trautmann et al. Is the proteomic composition of the salivary pellicle dependent on the substrate material?
Valente et al. Acquired enamel pellicle engineered peptides: effects on hydroxyapatite crystal growth
Md Fadilah et al. Discovery of bioactive peptides as therapeutic agents for skin wound repair
Fadilah et al. Discovery of bioactive peptides as therapeutic agents for skin wound repair
PT750672E (pt) Sequencias de adn para metaloproteases matriciais, sua preparacao e utilizacao.
Pääkkönen et al. Analysis of gene and protein expression in healthy and carious tooth pulp with cDNA microarray and two‐dimensional gel electrophoresis
Gonzalez et al. Analysis of the expression of the Wnt family of proteins and its modulatory role on cytokine expression in non activated and activated astroglial cells
WO2003028543A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees comprenant le diagnostic et le traitement de la maladie d'alzheimer
EP1597271B1 (fr) Peptides diriges contre des autoanticorps resultant de l'intolerance au froid, et leur utilisation
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
Jin et al. Role of 3-methacryloxypropyltrimethoxysilane in dentin bonding
Bennmann et al. Glycation of the high affinity NGF-receptor and RAGE leads to reduced ligand affinity